Summary
Pharmaceuticals in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
- The Asia-Pacific pharmaceuticals market had total revenues of $324.8m in 2018, representing a compound annual growth rate (CAGR) of 6.5% between 2014 and 2018.
- The performance of the market is forecast to accelerate, with an anticipated CAGR of 9% for the five-year period 2018-2023, which is expected to drive the market to a value of $500.6m by the end of 2023.
- South Korea and Japan contrast the performance of the region as a whole. Low rates of growth show those markets are mature and pressure is exerted on reducing costs within their healthcare systems.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Asia-Pacific
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Asia-Pacific
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Asia-Pacific pharmaceuticals market with five year forecasts
Reasons to buy
- What was the size of the Asia-Pacific pharmaceuticals market by value in 2018?
- What will be the size of the Asia-Pacific pharmaceuticals market in 2023?
- What factors are affecting the strength of competition in the Asia-Pacific pharmaceuticals market?
- How has the market performed over the last five years?
- How large is Asia-Pacific’s pharmaceuticals market in relation to its regional counterparts?
'
Table of Contents
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Daiichi Sankyo Co Ltd
Shanghai Pharmaceuticals
Takeda Pharmaceutical Company Limited
Yangtze River Pharmaceutical Group
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
List of Tables
Table 1: Asia-Pacific pharmaceuticals market value: $ billion, 2014-18
Table 2: Asia-Pacific pharmaceuticals market geography segmentation: $ billion, 2018
Table 3: Asia-Pacific pharmaceuticals market share: % share, by value, 2018
Table 4: Asia-Pacific pharmaceuticals market value forecast: $ billion, 2018-23
Table 5: Daiichi Sankyo Co Ltd: key facts
Table 6: Daiichi Sankyo Co Ltd: key financials ($)
Table 7: Daiichi Sankyo Co Ltd: key financials (¥)
Table 8: Daiichi Sankyo Co Ltd: key financial ratios
Table 9: Shanghai Pharmaceuticals: key facts
Table 10: Shanghai Pharmaceuticals: key financials ($)
Table 11: Shanghai Pharmaceuticals: key financials (CNY)
Table 12: Shanghai Pharmaceuticals: key financial ratios
Table 13: Takeda Pharmaceutical Company Limited: key facts
Table 14: Takeda Pharmaceutical Company Limited: key financials ($)
Table 15: Takeda Pharmaceutical Company Limited: key financials (¥)
Table 16: Takeda Pharmaceutical Company Limited: key financial ratios
Table 17: Yangtze River Pharmaceutical Group: key facts
List of Figures
Figure 1: Asia-Pacific pharmaceuticals market value: $ billion, 2014-18
Figure 2: Asia-Pacific pharmaceuticals market geography segmentation: % share, by value, 2018
Figure 3: Asia-Pacific pharmaceuticals market share: % share, by value, 2018
Figure 4: Asia-Pacific pharmaceuticals market value forecast: $ billion, 2018-23
Figure 5: Forces driving competition in the pharmaceuticals market in Asia-Pacific, 2018
Figure 6: Drivers of buyer power in the pharmaceuticals market in Asia-Pacific, 2018
Figure 7: Drivers of supplier power in the pharmaceuticals market in Asia-Pacific, 2018
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Asia-Pacific, 2018
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Asia-Pacific, 2018
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Asia-Pacific, 2018
Figure 11: Daiichi Sankyo Co Ltd: revenues & profitability
Figure 12: Daiichi Sankyo Co Ltd: assets & liabilities
Figure 13: Shanghai Pharmaceuticals: revenues & profitability
Figure 14: Shanghai Pharmaceuticals: assets & liabilities
Figure 15: Takeda Pharmaceutical Company Limited: revenues & profitability
Figure 16: Takeda Pharmaceutical Company Limited: assets & liabilities
